A groundbreaking approach slows tumor growth while boosting the immune system’s defense against cancer cells. Prostate cancer ranks as the second most common cancer among men globally. Despite recent ...

Our readers from across the county give their weekly take on the biggest issues impacting Kent and beyond. Some letters refer ...

Overtreatment of prostate cancer is increasing in the United States among men with limited life expectancy, a new s ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with me ...

NEW research has revealed potential links between agricultural pesticide exposure and higher rates of prostate cancer among ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other ...

According to Vesprini, the most common problem most men experience is that the prostate continues growing. While it might be ...

Students said Aponte was also instrumental in providing emotional support on campus after a deadly shooting at the school in ...

Prostate cancer patients may have long-term complications from treatment ... Nov. 7 (UPI) -- The U.S. Food and Drug ...